| Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. | |
| | |
MedLine Citation:
|
PMID: 22469521 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: Multiple myeloma(MM) affects mainly elderly persons and since the population of octogenarians increases, it is common to treat patients ≥80 years of age. These patients are often not included in clinical trials, thus, there is limited data on their characteristics and treatment outcome. PATIENTS AND METHODS: We retrospectively analyzed 682 consecutive, unselected patients with newly diagnosed symptomatic myeloma who started treatment between 1/1/2003 and 31/12/2010 RESULTS: We identified 155(23%) patients ≥80 years of age. Compared to patients <80 years, octogenarians had poorer performance status(P<0.001), anemia(p=0.006), low serum albumin(p=0.001) and advanced ISS(p<0.001). The median survival of patients≥80 years was 22 months and 14% died within 2 months from therapy initiation. The median survival of patients ≥80 years who received who received upfront novel agents was 26 months vs 17 months for those who did not. ECOG performance status ≤1 and frontline use of novel agents were independently associated with better survival. Response to first line therapy was associated with improved survival (29 vs.16 months, p=0.017). CONCLUSIONS: Patients ≥80 years of age present with features of advanced myeloma and impaired performance status. The addition of novel agents may improve their outcome but careful assessment and prospective clinical trials targeting the population of elderly patients is needed © 2012 John Wiley & Sons A/S. |
| | |
Authors:
|
Meletios A Dimopoulos; Efstathios Kastritis; Sossana Delimpasi; Eirini Katodritou; Eleftheria Hatzimichael; Marie-Christine Kyrtsonis; Panagiotis Repousis; Maria Tsirogianni; Zafiris Kartasis; Agapi Parcharidou; Michalis Michael; Eurydiki Michalis; Constantinos Tsatalas; Ekaterini Stefanoudaki; Eudoxia Hatjiharissi; Dimitra Gika; Argiris Symeonidis; Evangelos Terpos; Konstantinos Zervas; |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-4-3 |
Journal Detail:
|
Title: European journal of haematology Volume: - ISSN: 1600-0609 ISO Abbreviation: - Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-4-3 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8703985 Medline TA: Eur J Haematol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
© 2012 John Wiley & Sons A/S. |
Affiliation:
|
Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Intraventricularly injected Olig2-NSCs attenuate established relapsing-remitting EAE in mice.
Next Document: The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.